Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2019 - 2026)

Taysha Gene Therapies has disclosed Other Accumulated Expenses across 8 years of filings, most recently posting $784000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $784000.0, down 2.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $784000.0 (down 2.73% YoY), and the FY2025 annual result was $777000.0, up 3.32% from the prior year.
• Other Accumulated Expenses came in at $784000.0 for Q1 2026 at Taysha Gene Therapies, up from $777000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q1 2022 to a low of $650000.0 in Q4 2022.
• The 5-year median for Other Accumulated Expenses is $777000.0 (2024), against an average of $892588.2.
• Across the five-year window, Other Accumulated Expenses jumped 1139.06% in 2022 and sank 56.9% in 2023, its largest moves.
• Taysha Gene Therapies' Other Accumulated Expenses stood at $650000.0 in 2022, then climbed by 11.23% to $723000.0 in 2023, then gained by 4.01% to $752000.0 in 2024, then rose by 3.32% to $777000.0 in 2025, then climbed by 0.9% to $784000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $784000.0 (Q1 2026), $777000.0 (Q4 2025), and $749000.0 (Q3 2025), per Business Quant data.